FDA Approvals: Lorcaserin for Treatment of Obesity Lorcaserin is a serotonin 2C receptor agonist indicated for chronic weight management in adults when used in conjunction with a caloric restriction diet and increased physical activity. The effect of lorcaserin on cardiovascular morbidity and mortality has not been established. The second trip before the Food and Drug Administration appears to have done the trick: the agency approved lorcaserin (Belviq) for the treatment of obesity [1]. The approval follows an overwhelming vote by the Endocrinologic and Metabolic Drugs Advisory Committee in favor of lorcaserin as an adjunct to diet and exercise in patients with a body-mass index (BMI) > 30. For patients with weight-related comorbidities, such as hypertension, dyslipidemia, or type 2 diabetes, the drug is indicated for individuals with a BMI > 27. In October 2010, the FDA rej...